Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC), but lowered the price target from $40 to $35.

September 20, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics' price target has been lowered from $40 to $35 by Needham, though the 'Buy' rating is maintained.
The lowering of the price target by Needham could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100